Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Revenues down 5% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck
 
4QRevenue: $11.7 billion (-5%)

4Q Earnings: $1.4 billion (-7%)

YTD Revenues: $47.3 billion (-2%)

YTD Earnings: $6.7 billion (+6%)

Comments: Pharmaceutical sales were down 6% to $10.1 billion, including a 1% percent negative impact due to foreign exchange. Singulair sales were down 67% to $480 million. Cozaar/Hyzaar sales were down 26% to $315 million. Januvia sales were $1.1 billion in the quarter, up 18%. Zetia sales were $676 million, up 6%. Remicade sales were up 8% to $549 million. Janumet sales were up 17% to $452 million. Gardasil sales were up 61% to $442 million. Merck Animal Health sales totaled $898 million for the quarter, up 3%. Consumer Care sales were $395 million, up 9%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters